Can Medifast's Better Client Retention Support Revenue Stabilization?
MED's revenue is stabilizing as coach productivity and client retention improve, though a shrinking coach base continues to weigh on results.
Stock Taper 
MED
$11.44
▼ DOWN 0.61% (-0.07)
KEY STATISTICS
Market Cap$127.31 M
52w High$14.15
52w Low$9.22
Dividend Yield8.20%
FrequencyQuarterly
P/E-9.30
Volume84.15K
Shares Out.11.12M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Nicholas Johnson
COMPENSATION 2026
Salary$1,000,000
Stock Awards$4,567,664
Incentive Plan Pay$0
All Other Comp.$16,886
Total$5,584,551
ABOUT
SECTOR
Consumer Cyclical
WENT PUBLIC
December 30, 1993
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
380
PRICE TARGET
Target High$150.00
Target Low$12.00
Target Median$17.00
Target Consensus$59.67
UPCOMING EARNINGS
DateNov 9, 2026
DayMonday
Rev. Est.$71.30M
NOV
9
MON
ETFS HOLDING THIS STOCK
ETFS HOLDING
36
LISTED HERE
10
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
56.11%
HOLDERS
241
TOP 8 OF 241 · RANKED BY POSITION SIZE
PRICE
$11.44 ▼ DOWN 0.61% (−$0.07)About Medifast, Inc.
https://medifastinc.com ↗Medifast, Inc. manufactures and distributes weight management and health products under brands like OPTAVIA and Flavors of Home, selling through ecommerce in the U.S. and Asia-Pacific since 1980.
INDUSTRY
Personal Products & Services
A PRODUCT MEDIFAST, INC. IS KNOWN FOR
OPTAVIA ACTIVE
Launched in July 2023, OPTAVIA ACTIVE by Medifast offers sports nutrition products like EAAs Blend and Whey Protein to support fitness goals, marking Medifast's expansion into the sports nutrition market.
Medifast in 2025
SENTIMENT: − NEGATIVE
EARNINGS · NOVEMBER 2025
Medifast Reports Significant Revenue Decline and Net Loss in Q3 2025, Citing Challenges from GLP-1 Medications
In its third-quarter 2025 financial results, Medifast announced a 36.2% year-over-year revenue decrease to $89.4 million and a net loss of $2.3 million. The company attributed the downturn to a 35% decline in active earning OPTAVIA coaches, linking these challenges to the growing popularity of GLP-1 weight loss medications and a subsequent difficulty in client acquisition.
BUSINESS MODEL · OCTOBER 2025 · IN PROGRESS
Medifast Pivots from Weight Loss to a Broader Focus on Metabolic Health with "Metabolic Synchronization™"
In response to a challenging market and declining revenues, Medifast announced a strategic transformation to expand its focus from weight loss to the broader market of metabolic health. This shift is centered around a new scientific approach called "Metabolic Synchronization™," which aims to reverse metabolic dysfunction.
Latest News
EARLIER COVERAGE
Why Do You Keep Gaining Weight Back After Losing It
Baltimore, MD, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Weight comes back after weight loss when the conditions that drove it were never addressed during the weight loss phase. Trilivy™, a science-backed, coach-guided comprehensive metabolic health system, points to five factors research identifies as drivers of weight regain, rooted in body composition and habit infrastructure.
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
Baltimore, MD, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The signs of poor metabolic health can be difficult to analyze without a clinical framework. Trilivy™, a science-backed, coach-guided metabolic health system, points to five frequently overlooked patterns adults can recognize before noticeable weight and energy fluctuations.
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book5
Overall Score3
MOST RECENT ANALYST GRADES
GRADE SUMMARY
EQUAL WEIGHT 1
1 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 CURV | $2.52 | COMPARE |
 BSET | $21.43 | COMPARE |
 DIBS | $3.95 | COMPARE |
 CAAS | $4.36 | COMPARE |
 CLAR | $3.38 | COMPARE |
 AKA | $10.86 | COMPARE |
 KEQU | $33.55 | COMPARE |
 MB | $3.85 | COMPARE |
TRADES BY CONGRESS
HOUSE TRADES
Donna Shalala
Sale (Full)
2019-06-24
INSIDER TRADES
★
DIRECTOR
Chard Daniel R
Sale · 9.5K shares
2026-09-29
★
DIRECTOR
Chard Daniel R
Sale · 9.5K shares
2026-09-28
★
DIRECTOR
Kiai Parsa
Purchase · 1.2K shares
2026-08-26
★
DIRECTOR
Kiai Parsa
Purchase · 42.0K shares
2026-08-26